Skip to main content
U2BIO CO., LTD. logo

U2BIO CO., LTD. — Investor Relations & Filings

Ticker · 221800 ISIN · KR7221800006 KO Human health and social work activities
Open in API
Filings indexed 227 across all filing types
Latest filing 2021-12-08 Regulatory Filings
Country KR South Korea
Listing KO 221800

About U2BIO CO., LTD.

https://www.u2bio.co.kr/eng/main.do

U2BIO CO., LTD. is a healthcare technology company specializing in the integration of biotechnology (BT) and information technology (IT). The company provides a range of in vitro diagnostic services, including clinical laboratory tests and molecular diagnostics. Concurrently, it develops and offers digital healthcare solutions and medical IT services tailored for medical institutions such as hospitals and clinics. U2BIO focuses on delivering personalized healthcare services based on scientific data to support medical professionals and improve patient health outcomes.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure period for the purpose of holding an Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal notice of a corporate action. Given it is a regulatory announcement that does not fit into specific categories like dividend or share issuance, it falls under the general regulatory filing category.
2021-12-08 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 100% confidence The document is a formal notification regarding the results of an Investor Relations (IR) meeting held by U2Bio. It lists the date, location, attendees, and agenda of the meeting. Since it is a short regulatory announcement confirming that an IR event took place and where the materials can be found, rather than the presentation slides themselves, it falls under the category of a regulatory filing announcement.
2021-10-22 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into other specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a standard corporate disclosure notice.
2021-09-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a mandatory disclosure for major shareholders or executives when their ownership stake changes, which falls under the category of 'Major Shareholding Notification' (MRQ) in the provided schema, as it details the acquisition and conversion of convertible bonds into common stock by a major shareholder.
2021-08-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a mandatory regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership, specifically involving the conversion of convertible bonds into shares by a major shareholder (NDS Corporation) in the company U2Bio. This type of filing is a standard regulatory disclosure regarding significant shareholding thresholds and does not fit into other specific categories like M&A or Dividend announcements. Therefore, it is classified as a Regulatory Filing.
2021-08-03 Korean
전환청구권행사(제7회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the exercise of conversion rights (전환청구권 행사) for convertible bonds (CB). It details the number of shares issued, the conversion price, and the impact on the company's capital structure. This type of disclosure regarding capital changes and conversion of debt into equity falls under the 'Share Issue/Capital Change' category.
2021-07-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.